Mitochondrial Donation: Medicine Interview Case Study

AlphaMED Resources · https://alphamedicine.uk/Resources/cases/mitochondrial-donation

Mitochondrial donation and the Newcastle births

Mitochondrial donation is a licensed IVF technique that swaps the damaged mitochondria in an egg for healthy ones from a donor, so that a child carries far less of the faulty DNA behind a serious inherited disease. Newcastle reported eight babies born this way in July 2025, and experts say larger studies are still needed before its safety and benefit can be judged.

Summary

Mitochondrial donation is a form of IVF that replaces the damaged mitochondrial DNA in a mother's egg with healthy mitochondria from a donor's egg.
The disease it targets can cause heart and other major organ failure, stroke, dementia, blindness or deafness, and there is no cure.
The worry is that faulty DNA not fully removed could build up again in a child, and few families have been treated. Ghent ethicist Heidi Mertes said that reversal is a real danger for the offspring.
The Nuffield Council on Bioethics said in 2012 that the treatment could be ethical once proved safe and effective, and that the donor should not be called a mother or "third parent".
The Human Fertilisation and Embryology (Mitochondrial Donation) Regulations 2015 came into force on 29 October 2015, allowing treatment under licence. Newcastle Fertility Centre was granted the first licence in 2017.
In July 2025 Newcastle reported eight babies from seven women, all healthy at birth. The regulator, the HFEA, said 35 patients had been approved and 25 had undergone pronuclear transfer, the step that moves the nuclear DNA into a donor's egg, as of 1 July 2025. We found no later UK count.

Dig deeper

Some faulty DNA still passes to the child. In Newcastle's babies, carry over ranged from undetectable to 16%. Three babies had low levels, below the 80% level linked to clinical disease.
- Bert Smeets, a geneticist, said two children had a higher mutation load than the carry over, and that this was still a concern.
Follow up is still short. Newcastle's developmental study runs for 18 months.
The 2015 Regulations say the donor is not treated as the child's parent. A child can ask the HFEA for the donor's screening results and medical history, after counselling, but not for anything that could identify the donor.
Australia passed its own law, the Mitochondrial Donation Law Reform (Maeve's Law) Act.
- A programme led by Monash University, mitoHOPE, received its first preclinical licence in November 2025.
- The clinical trial has been delayed, and families may be able to start towards the end of 2027.
The same question of who decides for a baby who cannot agree arose in Indi Gregory.

Ethical issues

Principle	How it applies here
Autonomy	The mothers are adults with capacity. The Regulations allow treatment only where the HFEA finds a significant risk of serious mitochondrial disease. The eight children born in 2025 had no say, so their parents chose for them under parental responsibility.
Beneficence	The aim is a healthy child genetically related to the mother. The Newcastle study does not show an advantage over embryo testing, and one professor said it isn't clear that there is one.
Non maleficence	Carry over ran up to 16%, and assessments stop at age 5, so a later risk would not be seen in these children. Because mitochondrial DNA passes down the female line, a daughter born this way could pass the donor's DNA on to her own children.
Justice	Each treatment needs an HFEA determination for a named woman. The 2012 report asked for a centrally funded register that researchers could use for several decades.

Principle

How it applies here

Autonomy

The mothers are adults with capacity. The Regulations allow treatment only where the HFEA finds a significant risk of serious mitochondrial disease. The eight children born in 2025 had no say, so their parents chose for them under parental responsibility.

Beneficence

The aim is a healthy child genetically related to the mother. The Newcastle study does not show an advantage over embryo testing, and one professor said it isn't clear that there is one.

Non maleficence

Carry over ran up to 16%, and assessments stop at age 5, so a later risk would not be seen in these children. Because mitochondrial DNA passes down the female line, a daughter born this way could pass the donor's DNA on to her own children.

Justice

Each treatment needs an HFEA determination for a named woman. The 2012 report asked for a centrally funded register that researchers could use for several decades.

Interview questions

What do you know about mitochondrial donation and the Newcastle births?
What did the 2015 Regulations change in UK law?
You are a junior doctor counselling a woman who has a serious mitochondrial disease. She asks whether this treatment is better than embryo testing. What do you tell her, and what is still unknown?
Why did the Nuffield Council on Bioethics say that calling the donor a "third parent" is not legally or biologically accurate, and do you agree?
What is the case for and against offering the treatment to more families before the first children have been followed up for longer?
What are the arguments for and against letting a child find out who donated the egg?
Who should decide whether a treatment is safe enough for children who cannot consent to it?

Sources

cdn.nuffieldbioethics.orgcdn.nuffieldbioethics.org/…/Mitochondrial_DNA_disorders_summary_web.pdf
sciencemediacentre.orgsciencemediacentre.org/…/expert-reaction-to-two-papers-on-the-use-of-mitochondrial-do
legislation.gov.uklegislation.gov.uk/…/made
ncl.ac.ukncl.ac.uk/…/mitochondrialdonationtreatment
europepmc.orgeuropepmc.org/…/40689593
hfea.gov.ukhfea.gov.uk/…/hfea-comments-on-the-news-that-eight-babies-have-been-born-a
mito.org.aumito.org.au/…/mitochondrial-donation
pmc.ncbi.nlm.nih.govpmc.ncbi.nlm.nih.gov/…/PMC12294821

Photo: ZEISS Microscopy from Germany, CC BY-SA 2.0, via Wikimedia Commons, colour altered.

More NHS hot topics, medical ethics case studies and medical school interview questions are in AlphaMED Resources, which we add to and update through the application cycle.